查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2134690

選擇性兒茶酚-O-甲基轉移酵素抑制劑市場：全球市場預測，2026-2032年

Selective Catechol-O-Methyltransferase Inhibitor Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，選擇性兒茶酚-O-甲基轉移酵素抑制劑市場將成長至 7.0291 億美元，複合年成長率為 7.66%。

主要市場統計數據
基準年 2025 4.1929億美元
預計年份：2026年 4.4831億美元
預測年份：2032年 7.0291億美元
複合年成長率 (%) 7.66%

選擇性兒茶酚-O-甲基轉移酵素抑制劑：概述

選擇性兒茶酚-O-甲基甲基轉移酵素（COMT）抑制劑是一類旨在調節兒茶酚胺代謝的藥物，與左旋多巴聯合使用時，在控制帕金森氏症相關的運動變異方面具有重要的臨床意義。其價值取決於給藥便利性、耐受性、藥物交互作用情況、監管環境以及維持症狀持續控制的能力。臨床決策仍需個別化，考慮疾病分期、合併用藥、肝功能以及不良反應風險等因素。

治療方案的設計正朝著永續的、以患者為中心的症狀管理方向發展。

治療前景正從簡單的酶抑制轉向延長作用時間、簡化給藥方式以及更好地與現有帕金森氏症治療方案相結合。臨床醫師在選擇輔助性治療時，越來越關注治療反應的個別差異、運動障礙風險、睡眠相關症狀、胃腸道反應、用藥依從性障礙、看護者負擔等問題。監管機構和臨床關注的重點仍然是證明藥物具有顯著的功能獲益，而不僅僅依賴藥物動力學和評估量表的變化。

人工智慧可以促進藥物發現、臨床試驗設計和治療路徑的最佳化。

人工智慧可用於標靶驗證、分子篩檢、製劑最佳化，以及識別運動功能波動或治療相關不利事件高風險患者。在臨床開發中，機器學習技術可以輔助臨床試驗受試者招募、運動功能的數位化測量，以及從縱向記錄中檢測反應模式。實施這些技術需要具有代表性的資料集、透明的驗證、隱私保護和前瞻性檢驗。演算法輸出應作為神經科醫師判斷的補充，而非替代。

區域差異反映了醫療資源取得、監管以及專家的可近性。

北美地區通常提供先進的運動障礙醫療服務以及完善的監管和報銷機制，而拉丁美洲則可能面臨許多挑戰，例如專科醫生資源分配不均、診斷延遲以及藥品獲取途徑差異。歐洲的情況受到各國報銷政策、臨床指引一致性以及醫療體系組織結構差異的影響。中東地區在專科醫生數量和醫療資源取得方面存在顯著差異，而非洲則在診斷、持續治療和藥物供應方面面臨嚴峻挑戰。亞太地區擁有高度發展的醫療體系和強大的科研基礎設施，但經濟負擔、農村地區醫療資源匱乏以及專科醫生短缺仍然是部分地區的主要限制因素。

經濟集團和聯盟團體決定證據、取得途徑和政策的優先事項。

在東協市場，各成員國的監管程序、報銷機制和專家資源各不相同，通常需要採取國別針對性的方法。金磚國家擁有強大的研發和生產能力，但其公共衛生重點和藥品取得條件卻不盡相同。歐盟的優勢在於監管協調，但成員國在資金籌措和臨床應用方面仍有差異。七國集團（G7）的醫療衛生體系往往優先考慮證據品質、藥物安全監測、價值評估以及與專科醫療服務的整合。海灣合作理事會（GCC）成員國通常擁有相對完善的三級醫療衛生服務，但可能依賴集中採購和進口藥品。另一方面，北約成員國在建構穩健的藥品供應鏈方面有著通用的利益，但它們的醫療衛生體系結構差異顯著。

各國具體優先事項涵蓋創新能力到基本醫療保健的持續性等各個面向。

澳洲和加拿大優先考慮在廣闊的地域範圍內提供專科醫生服務，並推行循證醫療報銷。非洲（包括巴西、墨西哥、印度和南非）的醫療機構必須平衡都市區神經科集中就醫與成本效益和醫療服務連續性等挑戰之間的關係。中國、日本和韓國正在努力平衡不斷擴大的神經學研究能力與人口老化和不斷變化的醫療報銷體系所帶來的壓力。法國、德國、義大利、西班牙和英國高度重視基於指南的處方、醫療技術評估以及帕金森氏症患者的協調醫療服務，儘管這些措施的具體實施方式因地區而異。俄羅斯的醫療環境受到供應連續性、國內醫療服務可近性和區域差異等因素的影響。在美國，儘管擁有專科醫療基礎設施和臨床研究能力，但保險覆蓋範圍和患者的醫療費用承受能力存在顯著差異。

產業領導者應優先考慮差異化證據和保障患者獲得治療的機會。

領導者應開發以臨床意義顯著的運動變異性控制、實用劑量和明確的安全性特徵為重點的產品。實證項目應涵蓋不同的患者群體、相關的聯合治療、患者報告結果以及日常生活活動指標。准入策略應根據當地的報銷和採購實際情況進行調整，並輔以用藥依從性支持服務和臨床醫生教育。各機構還應建立嚴格的藥物安全監測系統，在真實臨床環境中監測治療依從性，並且僅在有據可查的管治、偏差測試、網路安全措施和臨床監督下使用人工智慧。

調查方法：整合來自臨床、監管和醫療保健系統的證據。

本執行摘要對已確立的關於選擇性COMT抑制劑、帕金森氏症治療路徑、藥物安全性、醫療保健系統可近性和區域供應的臨床研究結果進行了結構化的定性整合。根據分析要求，本文按地域、經濟和相關群體對解讀內容進行了分類。文中論述僅限於已廣泛記錄的特徵，避免未經證實的數值估算、市場規模估算、預測、市場佔有率或公司特定聲明。臨床和監管細節在實際應用前應參照現行權威指南進行審查。

結論：臨床效用取決於整合、證據和可近性。

選擇性COMT抑制劑在帕金森氏症治療中發揮輔助作用，其臨床價值取決於能否持續有效控制症狀、耐受性良好、是否適合治療方案以及患者能否獲得治療。隨著人們對更個人化療法的需求日益成長，對真實世界數據、數位化測量以及人工智慧的謹慎應用的期望不斷提高，這一領域正在發生變革。成功實施需要臨床醫生、患者、看護者、監管機構、保險公司和醫療保健系統之間的密切合作，而不同地區和國家的具體情況差異很大。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 選擇性兒茶酚-O-甲基轉移酵素酶抑制劑市場：依產品類型分類

  • 聯合治療
    • 多巴胺促效劑聯合治療
    • 左多巴聯合治療
  • 單藥治療

第8章 選擇性兒茶酚-O-甲基轉移酵素酶抑制劑市場：依適應症分類

  • 幕後花絮
  • 帕金森氏症

第9章 選擇性兒茶酚-O-甲基轉移酵素抑制劑市場：依治療領域分類

  • 第 1 行
  • 第二行
  • 第三行

第10章 選擇性兒茶酚-O-甲基轉移酵素抑制劑市場：以劑型分類

  • 膠囊
  • 分散片
  • 口服錠劑

第11章 選擇性兒茶酚-O-甲基轉移酵素抑制劑市場：依分子類型分類

  • 硝兒茶酚
  • 非硝基兒茶酚

第12章 選擇性兒茶酚-O-甲基轉移酵素酶抑制劑市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章 選擇性兒茶酚-O-甲基轉移酵素酶抑制劑市場：依最終用戶分類

  • 診所
  • 居家照護
  • 醫院

第14章 選擇性兒茶酚-O-甲基轉移酵素抑制劑市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第15章 選擇性兒茶酚-O-甲基轉移酵素酶抑制劑市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 選擇性兒茶酚-O-甲基轉移酵素抑制劑市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第18章：公司簡介

  • Ajanta Pharma
  • Alembic Pharmaceuticals
  • Amneal Pharmaceuticals
  • Aurobindo Pharma
  • Bausch Health Companies Inc.
  • Bial - Portela & Cª, SA
  • Cardinal Health Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Fosun Pharma
  • Hebei Ideal & Hightech Pharmaceutical
  • HEC Pharma
  • Hikma Pharmaceuticals PLC
  • Lupin Limited
  • Macleods Pharmaceuticals
  • Neurocrine Biosciences, Inc.
  • Novartis AG
  • Novast Laboratories
  • Ono Pharmaceutical Co., Ltd.
  • Orion Corporation
  • Rising Pharmaceuticals
  • SJZ No.4 Pharmaceutical
  • Sun Pharma
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

第19章 主要專家

Product Code: MRR-F774F6337040

The Selective Catechol-O-Methyltransferase Inhibitor Market is projected to grow by USD 702.91 million at a CAGR of 7.66% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 419.29 million
Estimated Year [2026] USD 448.31 million
Forecast Year [2032] USD 702.91 million
CAGR (%) 7.66%

Selective Catechol-O-Methyltransferase Inhibitors: Executive Overview

Selective catechol-O-methyltransferase (COMT) inhibitors are pharmacological agents designed to modify catecholamine metabolism, with the principal clinical relevance being management of motor fluctuations associated with Parkinson's disease when used alongside levodopa-based therapy. Their value is shaped by dosing convenience, tolerability, drug-drug interaction profiles, regulatory status, and the ability to support sustained symptom control. Clinical decision-making should remain individualized and account for disease stage, concomitant medicines, hepatic considerations, and adverse-effect risk.

Treatment Design Is Shifting Toward Durable, Patient-Centered Control

The therapeutic landscape is moving beyond simple enzyme inhibition toward longer duration of action, simpler administration, and improved integration with existing Parkinson's disease regimens. Clinicians increasingly weigh fluctuations in response, dyskinesia risk, sleep-related symptoms, gastrointestinal effects, adherence barriers, and caregiver burden when selecting adjunctive treatment. Regulatory and clinical attention also remains focused on demonstrating meaningful functional benefit rather than relying solely on pharmacokinetic or rating-scale changes.

Artificial Intelligence Can Strengthen Discovery, Trial Design, and Care Pathways

Artificial intelligence may contribute to target validation, molecular screening, formulation optimization, and identification of patients more likely to experience motor fluctuations or treatment-related adverse events. In clinical development, machine-learning methods can support trial recruitment, digital measurement of mobility, and detection of response patterns from longitudinal records. Implementation requires representative datasets, transparent validation, privacy safeguards, and prospective confirmation; algorithmic outputs should complement rather than replace neurologist judgment.

Regional Differences Reflect Access, Regulation, and Specialist Capacity

North America generally combines advanced movement-disorder services with established regulatory and reimbursement pathways, while Latin America may face uneven specialist availability, diagnostic delays, and differences in medicine access. Europe's landscape is influenced by national reimbursement decisions, clinical-guideline alignment, and cross-country variation in health-system organization. The Middle East contains substantial differences in specialist capacity and procurement structures, and Africa faces pronounced challenges involving diagnosis, continuity of care, and medicine availability. Asia-Pacific spans highly developed systems with strong research infrastructure alongside settings where affordability, rural access, and specialist shortages remain central constraints.

Economic and Alliance Groups Shape Evidence, Access, and Policy Priorities

ASEAN markets commonly require country-specific approaches because regulatory procedures, reimbursement systems, and specialist coverage differ across members. BRICS economies combine substantial research and manufacturing capabilities with varied public-health priorities and access conditions. The European Union benefits from regulatory coordination but retains national differences in funding and clinical adoption. G7 systems tend to emphasize evidence quality, pharmacovigilance, value assessment, and integration into specialist care. GCC countries often have comparatively well-resourced tertiary services but may rely on centralized procurement and imported therapies, while NATO members show wide variation in health-system structure despite shared interest in resilient pharmaceutical supply chains.

Country-Level Priorities Range From Innovation Capacity to Basic Continuity of Care

Australia and Canada emphasize specialist access across large geographies and evidence-based reimbursement. Brazil, Mexico, India, and South Africa-related African care settings must balance urban concentration of neurologists with affordability and continuity challenges. China, Japan, and South Korea combine expanding neurological research capabilities with aging-population pressures and evolving reimbursement frameworks. France, Germany, Italy, Spain, and the United Kingdom place strong emphasis on guideline-based prescribing, health-technology assessment, and coordinated Parkinson's services, although implementation differs by jurisdiction. Russia's care environment is influenced by supply continuity, domestic access considerations, and regional disparities. In the United States, specialist infrastructure and clinical research capacity coexist with substantial variation in insurance coverage and patient affordability.

Industry Leaders Should Prioritize Differentiated Evidence and Reliable Patient Access

Leaders should develop products around clinically meaningful control of motor fluctuations, practical dosing, and a clearly characterized safety profile. Evidence programs should include diverse patients, relevant concomitant therapies, patient-reported outcomes, and measures of daily functioning. Access strategies should be tailored to regional reimbursement and procurement realities, supported by adherence services and clinician education. Organizations should also establish rigorous pharmacovigilance, monitor real-world treatment persistence, and use artificial intelligence only under documented governance, bias testing, cybersecurity controls, and clinical oversight.

Methodology: Evidence Synthesis Across Clinical, Regulatory, and Health-System Dimensions

This executive summary uses a structured qualitative synthesis of established clinical knowledge concerning selective COMT inhibition, Parkinson's disease treatment pathways, medication safety, health-system access, and regional delivery conditions. Interpretation is organized across geographic, economic, and alliance groupings requested for the analysis. Claims are limited to broadly documented characteristics and avoid unsupported numerical estimates, market sizing, forecasts, market shares, or company-specific assertions. Clinical and regulatory details should be confirmed against current authoritative guidance before operational use.

Conclusion: Clinical Utility Depends on Integration, Evidence, and Access

Selective COMT inhibitors occupy an adjunctive role in Parkinson's disease care, where their practical value depends on sustained symptom management, tolerability, regimen fit, and patient access. The field is being shaped by more individualized treatment, stronger real-world evidence expectations, digital measurement, and cautious adoption of artificial intelligence. Successful implementation will require coordination among clinicians, patients, caregivers, regulators, payers, and health systems across markedly different regional and national contexts.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Selective Catechol-O-Methyltransferase Inhibitor Market, by Product Type

  • 7.1. Introduction
  • 7.2. Combination Therapy
    • 7.2.1. Dopamine Agonist Combination
    • 7.2.2. Levodopa Combination
  • 7.3. Single Agent

8. Selective Catechol-O-Methyltransferase Inhibitor Market, by Indication

  • 8.1. Introduction
  • 8.2. Off Episodes
  • 8.3. Parkinson's Disease

9. Selective Catechol-O-Methyltransferase Inhibitor Market, by Treatment Line

  • 9.1. Introduction
  • 9.2. First Line
  • 9.3. Second Line
  • 9.4. Third Line

10. Selective Catechol-O-Methyltransferase Inhibitor Market, by Formulation

  • 10.1. Introduction
  • 10.2. Capsules
  • 10.3. Dispersible Tablets
  • 10.4. Oral Tablets

11. Selective Catechol-O-Methyltransferase Inhibitor Market, by Molecular Type

  • 11.1. Introduction
  • 11.2. Nitrocatechol
  • 11.3. Non Nitrocatechol

12. Selective Catechol-O-Methyltransferase Inhibitor Market, by Distribution Channel

  • 12.1. Introduction
  • 12.2. Hospital Pharmacies
  • 12.3. Online Pharmacies
  • 12.4. Retail Pharmacies

13. Selective Catechol-O-Methyltransferase Inhibitor Market, by End User

  • 13.1. Introduction
  • 13.2. Clinics
  • 13.3. Home Care
  • 13.4. Hospitals

14. Selective Catechol-O-Methyltransferase Inhibitor Market, by Region

  • 14.1. Introduction
  • 14.2. Asia-Pacific
  • 14.3. North America
  • 14.4. Latin America
  • 14.5. Europe
  • 14.6. Middle East
  • 14.7. Africa

15. Selective Catechol-O-Methyltransferase Inhibitor Market, by Group

  • 15.1. Introduction
  • 15.2. ASEAN
  • 15.3. GCC
  • 15.4. European Union
  • 15.5. BRICS
  • 15.6. G7
  • 15.7. NATO

16. Selective Catechol-O-Methyltransferase Inhibitor Market, by Country

  • 16.1. Introduction
  • 16.2. United States
  • 16.3. Canada
  • 16.4. Mexico
  • 16.5. Brazil
  • 16.6. United Kingdom
  • 16.7. Germany
  • 16.8. France
  • 16.9. Russia
  • 16.10. Italy
  • 16.11. Spain
  • 16.12. China
  • 16.13. India
  • 16.14. Japan
  • 16.15. Australia
  • 16.16. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2025
  • 17.2. Market Concentration Analysis, 2025
    • 17.2.1. Concentration Ratio (CR)
    • 17.2.2. Herfindahl Hirschman Index (HHI)
  • 17.3. Recent Developments & Impact Analysis, 2025
  • 17.4. Product Portfolio Analysis, 2025
  • 17.5. Benchmarking Analysis, 2025

18. Company Profiles

  • 18.1. Ajanta Pharma
  • 18.2. Alembic Pharmaceuticals
  • 18.3. Amneal Pharmaceuticals
  • 18.4. Aurobindo Pharma
  • 18.5. Bausch Health Companies Inc.
  • 18.6. Bial - Portela & Cª, S.A.
  • 18.7. Cardinal Health Inc.
  • 18.8. Dr. Reddy's Laboratories Ltd.
  • 18.9. Fosun Pharma
  • 18.10. Hebei Ideal & Hightech Pharmaceutical
  • 18.11. HEC Pharma
  • 18.12. Hikma Pharmaceuticals PLC
  • 18.13. Lupin Limited
  • 18.14. Macleods Pharmaceuticals
  • 18.15. Neurocrine Biosciences, Inc.
  • 18.16. Novartis AG
  • 18.17. Novast Laboratories
  • 18.18. Ono Pharmaceutical Co., Ltd.
  • 18.19. Orion Corporation
  • 18.20. Rising Pharmaceuticals
  • 18.21. SJZ No.4 Pharmaceutical
  • 18.22. Sun Pharma
  • 18.23. Sun Pharmaceutical Industries Ltd.
  • 18.24. Teva Pharmaceutical Industries Ltd.
  • 18.25. Viatris Inc.

19. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global Selective Catechol-O-Methyltransferase Inhibitor Market, Years Considered for the Study
  • FIGURE 2. Global Selective Catechol-O-Methyltransferase Inhibitor Market, Research Design
  • FIGURE 3. Global Selective Catechol-O-Methyltransferase Inhibitor Market, Research Framework
  • FIGURE 4. Global Selective Catechol-O-Methyltransferase Inhibitor Market, Data Triangulation
  • FIGURE 5. Global Selective Catechol-O-Methyltransferase Inhibitor Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Product Type, 2025 vs 2032 (%)
  • FIGURE 7. Global Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Indication, 2025 vs 2032 (%)
  • FIGURE 9. Global Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Treatment Line, 2025 vs 2032 (%)
  • FIGURE 11. Global Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Treatment Line, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Formulation, 2025 vs 2032 (%)
  • FIGURE 13. Global Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Formulation, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Molecular Type, 2025 vs 2032 (%)
  • FIGURE 15. Global Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Molecular Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Distribution Channel, 2025 vs 2032 (%)
  • FIGURE 17. Global Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 18. Global Selective Catechol-O-Methyltransferase Inhibitor Market Size, by End User, 2025 vs 2032 (%)
  • FIGURE 19. Global Selective Catechol-O-Methyltransferase Inhibitor Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 20. Global Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 21. Global Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 22. Global Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 23. Global Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 24. Global Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 25. Global Selective Catechol-O-Methyltransferase Inhibitor Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global Selective Catechol-O-Methyltransferase Inhibitor Market Segmentation & Coverage
  • TABLE 2. Global Selective Catechol-O-Methyltransferase Inhibitor Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 4. Global Combination Therapy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global Combination Therapy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global Combination Therapy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Dopamine Agonist Combination Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Dopamine Agonist Combination Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Dopamine Agonist Combination Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global Levodopa Combination Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 11. Global Levodopa Combination Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 12. Global Levodopa Combination Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 13. Global Single Agent Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 14. Global Single Agent Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 15. Global Single Agent Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 16. Global Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 17. Global Off Episodes Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 18. Global Off Episodes Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 19. Global Off Episodes Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 20. Global Parkinson's Disease Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 21. Global Parkinson's Disease Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 22. Global Parkinson's Disease Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 23. Global Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Treatment Line, 2017-2032 (USD Million)
  • TABLE 24. Global First Line Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 25. Global First Line Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 26. Global First Line Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 27. Global Second Line Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 28. Global Second Line Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 29. Global Second Line Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 30. Global Third Line Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 31. Global Third Line Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 32. Global Third Line Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 33. Global Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 34. Global Capsules Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 35. Global Capsules Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 36. Global Capsules Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 37. Global Dispersible Tablets Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 38. Global Dispersible Tablets Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 39. Global Dispersible Tablets Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 40. Global Oral Tablets Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 41. Global Oral Tablets Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 42. Global Oral Tablets Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 43. Global Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Molecular Type, 2017-2032 (USD Million)
  • TABLE 44. Global Nitrocatechol Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 45. Global Nitrocatechol Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 46. Global Nitrocatechol Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 47. Global Non Nitrocatechol Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 48. Global Non Nitrocatechol Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 49. Global Non Nitrocatechol Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 50. Global Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 51. Global Hospital Pharmacies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 52. Global Hospital Pharmacies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 53. Global Hospital Pharmacies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 54. Global Online Pharmacies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 55. Global Online Pharmacies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 56. Global Online Pharmacies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 57. Global Retail Pharmacies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 58. Global Retail Pharmacies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 59. Global Retail Pharmacies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 60. Global Selective Catechol-O-Methyltransferase Inhibitor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 61. Global Clinics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 62. Global Clinics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 63. Global Clinics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 64. Global Home Care Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 65. Global Home Care Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 66. Global Home Care Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 67. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 68. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 69. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 70. Global Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 71. Asia-Pacific Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 72. Asia-Pacific Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 73. Asia-Pacific Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Combination Therapy, 2017-2032 (USD Million)
  • TABLE 74. Asia-Pacific Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 75. Asia-Pacific Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Treatment Line, 2017-2032 (USD Million)
  • TABLE 76. Asia-Pacific Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 77. Asia-Pacific Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Molecular Type, 2017-2032 (USD Million)
  • TABLE 78. Asia-Pacific Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 79. Asia-Pacific Selective Catechol-O-Methyltransferase Inhibitor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 80. North America Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 81. North America Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 82. North America Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Combination Therapy, 2017-2032 (USD Million)
  • TABLE 83. North America Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 84. North America Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Treatment Line, 2017-2032 (USD Million)
  • TABLE 85. North America Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 86. North America Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Molecular Type, 2017-2032 (USD Million)
  • TABLE 87. North America Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 88. North America Selective Catechol-O-Methyltransferase Inhibitor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 89. Latin America Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 90. Latin America Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 91. Latin America Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Combination Therapy, 2017-2032 (USD Million)
  • TABLE 92. Latin America Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 93. Latin America Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Treatment Line, 2017-2032 (USD Million)
  • TABLE 94. Latin America Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 95. Latin America Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Molecular Type, 2017-2032 (USD Million)
  • TABLE 96. Latin America Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 97. Latin America Selective Catechol-O-Methyltransferase Inhibitor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 98. Europe Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 99. Europe Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 100. Europe Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Combination Therapy, 2017-2032 (USD Million)
  • TABLE 101. Europe Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 102. Europe Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Treatment Line, 2017-2032 (USD Million)
  • TABLE 103. Europe Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 104. Europe Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Molecular Type, 2017-2032 (USD Million)
  • TABLE 105. Europe Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 106. Europe Selective Catechol-O-Methyltransferase Inhibitor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 107. Middle East Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 108. Middle East Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 109. Middle East Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Combination Therapy, 2017-2032 (USD Million)
  • TABLE 110. Middle East Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 111. Middle East Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Treatment Line, 2017-2032 (USD Million)
  • TABLE 112. Middle East Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 113. Middle East Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Molecular Type, 2017-2032 (USD Million)
  • TABLE 114. Middle East Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 115. Middle East Selective Catechol-O-Methyltransferase Inhibitor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 116. Africa Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 117. Africa Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 118. Africa Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Combination Therapy, 2017-2032 (USD Million)
  • TABLE 119. Africa Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 120. Africa Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Treatment Line, 2017-2032 (USD Million)
  • TABLE 121. Africa Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 122. Africa Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Molecular Type, 2017-2032 (USD Million)
  • TABLE 123. Africa Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 124. Africa Selective Catechol-O-Methyltransferase Inhibitor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 125. Global Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 126. ASEAN Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 127. ASEAN Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 128. ASEAN Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Combination Therapy, 2017-2032 (USD Million)
  • TABLE 129. ASEAN Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 130. ASEAN Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Treatment Line, 2017-2032 (USD Million)
  • TABLE 131. ASEAN Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 132. ASEAN Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Molecular Type, 2017-2032 (USD Million)
  • TABLE 133. ASEAN Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 134. ASEAN Selective Catechol-O-Methyltransferase Inhibitor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 135. GCC Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 136. GCC Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 137. GCC Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Combination Therapy, 2017-2032 (USD Million)
  • TABLE 138. GCC Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 139. GCC Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Treatment Line, 2017-2032 (USD Million)
  • TABLE 140. GCC Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 141. GCC Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Molecular Type, 2017-2032 (USD Million)
  • TABLE 142. GCC Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 143. GCC Selective Catechol-O-Methyltransferase Inhibitor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 144. European Union Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 145. European Union Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 146. European Union Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Combination Therapy, 2017-2032 (USD Million)
  • TABLE 147. European Union Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 148. European Union Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Treatment Line, 2017-2032 (USD Million)
  • TABLE 149. European Union Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 150. European Union Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Molecular Type, 2017-2032 (USD Million)
  • TABLE 151. European Union Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 152. European Union Selective Catechol-O-Methyltransferase Inhibitor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 153. BRICS Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 154. BRICS Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 155. BRICS Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Combination Therapy, 2017-2032 (USD Million)
  • TABLE 156. BRICS Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 157. BRICS Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Treatment Line, 2017-2032 (USD Million)
  • TABLE 158. BRICS Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 159. BRICS Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Molecular Type, 2017-2032 (USD Million)
  • TABLE 160. BRICS Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 161. BRICS Selective Catechol-O-Methyltransferase Inhibitor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 162. G7 Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 163. G7 Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 164. G7 Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Combination Therapy, 2017-2032 (USD Million)
  • TABLE 165. G7 Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 166. G7 Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Treatment Line, 2017-2032 (USD Million)
  • TABLE 167. G7 Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 168. G7 Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Molecular Type, 2017-2032 (USD Million)
  • TABLE 169. G7 Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 170. G7 Selective Catechol-O-Methyltransferase Inhibitor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 171. NATO Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 172. NATO Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 173. NATO Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Combination Therapy, 2017-2032 (USD Million)
  • TABLE 174. NATO Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 175. NATO Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Treatment Line, 2017-2032 (USD Million)
  • TABLE 176. NATO Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 177. NATO Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Molecular Type, 2017-2032 (USD Million)
  • TABLE 178. NATO Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 179. NATO Selective Catechol-O-Methyltransferase Inhibitor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 180. Global Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 181. United States Selective Catechol-O-Methyltransferase Inhibitor Market Size, 2017-2032 (USD Million)
  • TABLE 182. United States Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 183. United States Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Combination Therapy, 2017-2032 (USD Million)
  • TABLE 184. United States Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 185. United States Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Treatment Line, 2017-2032 (USD Million)
  • TABLE 186. United States Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 187. United States Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Molecular Type, 2017-2032 (USD Million)
  • TABLE 188. United States Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 189. United States Selective Catechol-O-Methyltransferase Inhibitor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 190. Canada Selective Catechol-O-Methyltransferase Inhibitor Market Size, 2017-2032 (USD Million)
  • TABLE 191. Canada Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 192. Canada Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Combination Therapy, 2017-2032 (USD Million)
  • TABLE 193. Canada Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 194. Canada Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Treatment Line, 2017-2032 (USD Million)
  • TABLE 195. Canada Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 196. Canada Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Molecular Type, 2017-2032 (USD Million)
  • TABLE 197. Canada Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 198. Canada Selective Catechol-O-Methyltransferase Inhibitor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 199. Mexico Selective Catechol-O-Methyltransferase Inhibitor Market Size, 2017-2032 (USD Million)
  • TABLE 200. Mexico Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 201. Mexico Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Combination Therapy, 2017-2032 (USD Million)
  • TABLE 202. Mexico Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 203. Mexico Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Treatment Line, 2017-2032 (USD Million)
  • TABLE 204. Mexico Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 205. Mexico Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Molecular Type, 2017-2032 (USD Million)
  • TABLE 206. Mexico Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 207. Mexico Selective Catechol-O-Methyltransferase Inhibitor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 208. Brazil Selective Catechol-O-Methyltransferase Inhibitor Market Size, 2017-2032 (USD Million)
  • TABLE 209. Brazil Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 210. Brazil Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Combination Therapy, 2017-2032 (USD Million)
  • TABLE 211. Brazil Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 212. Brazil Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Treatment Line, 2017-2032 (USD Million)
  • TABLE 213. Brazil Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 214. Brazil Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Molecular Type, 2017-2032 (USD Million)
  • TABLE 215. Brazil Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 216. Brazil Selective Catechol-O-Methyltransferase Inhibitor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 217. United Kingdom Selective Catechol-O-Methyltransferase Inhibitor Market Size, 2017-2032 (USD Million)
  • TABLE 218. United Kingdom Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 219. United Kingdom Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Combination Therapy, 2017-2032 (USD Million)
  • TABLE 220. United Kingdom Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 221. United Kingdom Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Treatment Line, 2017-2032 (USD Million)
  • TABLE 222. United Kingdom Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 223. United Kingdom Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Molecular Type, 2017-2032 (USD Million)
  • TABLE 224. United Kingdom Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 225. United Kingdom Selective Catechol-O-Methyltransferase Inhibitor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 226. Germany Selective Catechol-O-Methyltransferase Inhibitor Market Size, 2017-2032 (USD Million)
  • TABLE 227. Germany Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 228. Germany Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Combination Therapy, 2017-2032 (USD Million)
  • TABLE 229. Germany Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 230. Germany Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Treatment Line, 2017-2032 (USD Million)
  • TABLE 231. Germany Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 232. Germany Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Molecular Type, 2017-2032 (USD Million)
  • TABLE 233. Germany Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 234. Germany Selective Catechol-O-Methyltransferase Inhibitor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 235. France Selective Catechol-O-Methyltransferase Inhibitor Market Size, 2017-2032 (USD Million)
  • TABLE 236. France Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 237. France Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Combination Therapy, 2017-2032 (USD Million)
  • TABLE 238. France Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 239. France Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Treatment Line, 2017-2032 (USD Million)
  • TABLE 240. France Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 241. France Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Molecular Type, 2017-2032 (USD Million)
  • TABLE 242. France Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 243. France Selective Catechol-O-Methyltransferase Inhibitor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 244. Russia Selective Catechol-O-Methyltransferase Inhibitor Market Size, 2017-2032 (USD Million)
  • TABLE 245. Russia Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 246. Russia Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Combination Therapy, 2017-2032 (USD Million)
  • TABLE 247. Russia Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 248. Russia Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Treatment Line, 2017-2032 (USD Million)
  • TABLE 249. Russia Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 250. Russia Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Molecular Type, 2017-2032 (USD Million)
  • TABLE 251. Russia Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 252. Russia Selective Catechol-O-Methyltransferase Inhibitor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 253. Italy Selective Catechol-O-Methyltransferase Inhibitor Market Size, 2017-2032 (USD Million)
  • TABLE 254. Italy Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 255. Italy Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Combination Therapy, 2017-2032 (USD Million)
  • TABLE 256. Italy Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 257. Italy Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Treatment Line, 2017-2032 (USD Million)
  • TABLE 258. Italy Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 259. Italy Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Molecular Type, 2017-2032 (USD Million)
  • TABLE 260. Italy Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 261. Italy Selective Catechol-O-Methyltransferase Inhibitor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 262. Spain Selective Catechol-O-Methyltransferase Inhibitor Market Size, 2017-2032 (USD Million)
  • TABLE 263. Spain Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 264. Spain Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Combination Therapy, 2017-2032 (USD Million)
  • TABLE 265. Spain Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 266. Spain Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Treatment Line, 2017-2032 (USD Million)
  • TABLE 267. Spain Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 268. Spain Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Molecular Type, 2017-2032 (USD Million)
  • TABLE 269. Spain Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 270. Spain Selective Catechol-O-Methyltransferase Inhibitor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 271. China Selective Catechol-O-Methyltransferase Inhibitor Market Size, 2017-2032 (USD Million)
  • TABLE 272. China Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 273. China Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Combination Therapy, 2017-2032 (USD Million)
  • TABLE 274. China Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 275. China Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Treatment Line, 2017-2032 (USD Million)
  • TABLE 276. China Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 277. China Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Molecular Type, 2017-2032 (USD Million)
  • TABLE 278. China Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 279. China Selective Catechol-O-Methyltransferase Inhibitor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 280. India Selective Catechol-O-Methyltransferase Inhibitor Market Size, 2017-2032 (USD Million)
  • TABLE 281. India Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 282. India Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Combination Therapy, 2017-2032 (USD Million)
  • TABLE 283. India Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 284. India Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Treatment Line, 2017-2032 (USD Million)
  • TABLE 285. India Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 286. India Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Molecular Type, 2017-2032 (USD Million)
  • TABLE 287. India Selective Catechol-O-Methyltransferase Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 288. India Selective Catechol-O-Methyltransferase Inhibitor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 289. Japan Selective Catechol-O-Methyltransferase Inhibitor Market Size, 2017-2032 (USD Million)
  • TABLE 290. Japan Selective Catechol-O-M